Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

NCT02973503 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

117

Enrollment

OTHER

Sponsor class

Conditions

Chronic HCV Infection

Interventions

DRUG: Elbasvir/Grazoprevir Fixed Dose Combination

Sponsor

University Hospital, Clermont-Ferrand

Collaborators

[object Object]